Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

IVUS improves outcomes in long lesions with DES

Original title: Randomized Comparison of Clinical Outcomes between Intravascular Ultrasound and Angiography-Guided Drug-Eluting Stent Implantation for Long Coronary Artery Stenosis. Reference: Jung-Sun Kim et al. J Am Coll Cardiol Intv 2013. Article in press.

Treating long lesions is difficult and the chance of instant thrombosis may be higher in these lesions. Coronary intravascular ultrasound (IVUS) can help in this context, however the information in our possession comes from retrospective and nonrandomized studies. No trial so far has evaluated the utility of IVUS in long lesions treated with drug-eluting stents (DES). The population of this study arose from RESET, (Real Safety and Efficacy of a 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stents Implantation). A pre-specified population with long lesions, (≥ 28 mm), were randomized to the use of IVUS or angiography only to guide angioplasty. The primary endpoint was a composite of cardiac death, myocardial infarction, stent thrombosis or target vessel revascularization (TVR) annually. 

A total of 543 patients were randomized of which 269 were assigned to IVUS guidance and 274 guided only by angiography. Despite the assigned treatment, 13 patients, (4.8%), of the IVUS branch finally did not receive it, 41 patients (15%) of the angiography branch finally received IVUS. In the intention analysis for treatment, post expansion was performed more frequently in those patients who used IVUS, (54.6% versus 44.5%, p = 0.03), although the minimum diameter post intervention was not different between the two branches. At one year of follow up, the combined end point was lower in the IVUS branch but did not reach statistical significance, (4.5% versus 7.3%, p = 0.16), at the time we conducted the analysis, so eventually was used but not for intention to treatment; the difference in the combined end point was then significant, (4% versus 8.1%, p = 0.048).

Conclusion: 

The strategy of routine using IVUS in the intention to treatment analysis did not improve the combined end point after one year. When the decision to use it relys on the operator it improves outcomes, although this data should be confirmed.

Commentary: 

The observed crossover prevents definitive conclusions but also adds that it was not authenticated with the information obtained from IVUS, (the post expansion was left to surgeon discretion). It is also a limitation that it was not mandatory to evaluate the artery prior to the IVUS assessment but after stenting, in fact only half of those receiving IVUS were evaluated previously and this could have wasted a lot of potentially useful information, (i.e. the perfect stent size). Finally the one year follow up and the inadequacy of the sample, (events on angiography branch were lower than expected), leaves the question open to debate. Probably the use of IVUS is suitable but only when surgeons are comfortable with it and can interpret information to change strategy if differences arise with angiography.

SOLACI.ORG

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...